RNAi-mediated inhibition of PDGF-D leads to decreased cell growth, invasion and angiogenesis in the SGC-7901 gastric cancer xenograft model

Platelet-derived growth factor-D (PDGF-D) plays an important role in many types of human cancer. However, little is known about the function of this gene in gastric cancer. Here we demonstrated that PDGF-D is commonly overexpressed in gastric cancer. Silencing of PDGF-D using RNA interference significantly attenuated the proliferation and invasion potentials of SGC-7901 gastric cancer cells in which PDGF-D is overexpressed. Moreover, suppression of PDGF-D expression resulted in less activation of β-catenin and its downstream effector genes, cyclin D1 and matrix metalloproteinases, which are known to be involved in cell proliferation and invasion, respectively. Further, downregulation of PDGF-D remarkably reduced VEGF expression and secretion and proangiogenic activities of SGC-7901 cells in vitro. Most importantly, PDGF-D downregulation caused a significant decrease in tumor growth and angiogenesis in a SGC-7901 xenograft model. Together these findings suggest that PDGF-D is involved in the promotion of gastric cancer growth, invasion and angiogenesis, and RNAi-mediated silencing of this gene may thus offer a promising therapeutic strategy for PDGF-D-overexpressing gastric cancer.

[1]  T. Wang,et al.  p53 inhibition of AP1-dependent TFF2 expression induces apoptosis and inhibits cell migration in gastric cancer cells. , 2009, American journal of physiology. Gastrointestinal and liver physiology.

[2]  Michael Chopp,et al.  ADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation , 2009, Cancer biology & therapy.

[3]  H. Ohdan,et al.  Laminin gamma2 mediates Wnt5a-induced invasion of gastric cancer cells. , 2009, Gastroenterology.

[4]  Zhiwei Wang,et al.  PDGF-D signaling: a novel target in cancer therapy. , 2009, Current drug targets.

[5]  Xuchao Xue,et al.  A small interfering RNA targeting osteopontin as gastric cancer therapeutics. , 2008, Cancer letters.

[6]  S. Tsujitani,et al.  Intraperitoneal administration of a small interfering RNA targeting nuclear factor‐kappa B with paclitaxel successfully prolongs the survival of xenograft model mice with peritoneal metastasis of gastric cancer , 2008, International journal of cancer.

[7]  Takashi Nakashima,et al.  Wnt1 overexpression promotes tumour progression in non-small cell lung cancer. , 2008, European journal of cancer.

[8]  Zhiwei Wang,et al.  Platelet‐Derived Growth Factor‐D Overexpression Contributes to Epithelial‐Mesenchymal Transition of PC3 Prostate Cancer Cells , 2008, Stem cells.

[9]  S. Fumoto,et al.  Gene therapy for gastric diseases. , 2008, Current gene therapy.

[10]  H. Tomita,et al.  Development of gastric tumors in Apc(Min/+) mice by the activation of the beta-catenin/Tcf signaling pathway. , 2007, Cancer research.

[11]  John J. Rossi,et al.  Strategies for silencing human disease using RNA interference , 2007, Nature Reviews Genetics.

[12]  N. Arber,et al.  Suppression of gastric cancer cell growth by targeting the β‐catenin/T‐cell factor pathway , 2007, Cancer.

[13]  B. Aronow,et al.  beta-Catenin/Wnt signaling regulates expression of the membrane type 3 matrix metalloproteinase in gastric cancer. , 2006, Cancer research.

[14]  G. Shackleford,et al.  Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis. , 2006, Cancer research.

[15]  Zhiwei Wang,et al.  Antitumor activity of epidermal growth factor receptor-related protein is mediated by inactivation of ErbB receptors and nuclear factor-kappaB in pancreatic cancer. , 2006, Cancer research.

[16]  Ricky T. Tong,et al.  Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. , 2005, Cancer research.

[17]  M. Stevenson.  Therapeutic potential of RNA interference , 2004, The New England journal of medicine.

[18]  R. Berardi,et al.  Gastric cancer treatment: a systematic review. , 2004, Oncology reports.

[19]  H. Kim,et al.  A Potential Oncogenic Activity of Platelet-Derived Growth Factor D in Prostate Cancer Progression , 2004, Cancer Research.

[20]  C. Bucana,et al.  Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  Chris Albanese,et al.  Gastrin-induced gastric adenocarcinoma growth is mediated through cyclin D1. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[22]  Robert N. Taylor,et al.  beta-Catenin regulates vascular endothelial growth factor expression in colon cancer. , 2003, Cancer research.

[23]  Xuri Li,et al.  PDGF-D is a potent transforming and angiogenic growth factor , 2003, Oncogene.

[24]  H. Kim,et al.  Platelet-derived growth factor signaling and human cancer. , 2003, Journal of biochemistry and molecular biology.

[25]  Lois E. H. Smith,et al.  Molecular profiling of angiogenesis markers. , 2002, The American journal of pathology.

[26]  M. Israel,et al.  Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. , 2002, Cancer research.

[27]  M. Jeffers,et al.  Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer. , 2002, Cancer research.

[28]  C. Albanese,et al.  The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  S. Rosenkranz,et al.  Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. , 1999, Growth factors.

[30]  F. McCormick,et al.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. , 1999, Nature.

[31]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[32]  S. Fox,et al.  Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. , 1996, European journal of cancer.

[33]  T. Deuel,et al.  Polypeptide growth factors: roles in normal and abnormal cell growth. , 1987, Annual review of cell biology.